Accreditation/Credit Designation
Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by an educational grant from Seagen Inc.
Oncology Consultations®: Applying the Latest Advances in Treatment of PTCL and CTCL with an Eye Toward the Future of Care
Release Date: December 23, 2021
Expiration Date: December 23, 2022
Activity Overview
Acknowledgement of Commercial Support
This activity is supported by an educational grant from Seagen Inc.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate. |
Target Audience
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Personalize decision-making for patients with T-cell lymphoma by utilizing testing strategies to differentiate diagnosis and identify molecular and phenotypic markers
- Integrate recent clinical trial evidence for the management of patients with peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphomas (CTCL)
- Devise proactive strategies to monitor for and manage treatment-associated toxicities among patients with PTCL and CTCL in frontline and relapsed/refractory settings
- Describe emerging strategies in the management of patients with PTCL and CTCL based on recent evidence and planned as well as ongoing clinical trials
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
Faculty
Member
Memorial Sloan Kettering Cancer Center
Attending Physician
Memorial Hospital
Professor of Medicine
Weill Cornell Medical College
New York, New York
Disclosures: Grant/Research Support: ADC Therapeutics, Affimed, Celgene, CRISPR Therapeutics, Daiichi Sankyo, Kyowa Hakko Kirin, Millennium /Takeda, Seagen Inc., Verastem/Secura Bio; Consultant: Acrotech Biopharma, Daiichi Sankyo, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceutical, Seagen Inc., Secura Bio, Shoreline Biosciences, Inc., Takeda, and Tubulis.
Associate Attending
Lymphoma Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Grant/Research Support: ADC Therapeutics, BeiGene, Miragen, Seagen Inc., Merck, Bristol Myers Squibb, and Incyte; Consultant: Janpix Ltd., Merck, Seagen Inc., Imbrium Therapeutics L.P./Purdue, and Takeda.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.
